Cancer Genetics Announces 39% Revenue Increase And Provides Recent Company Highlights
RUTHERFORD, N.J., May 10, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the first quarter ended March 31, 2016.
Financial results and highlights for the quarter ended March 31, 2016 include:
Financial results and highlights for the quarter ended March 31, 2016 include: